SmartCelleTM – A New Platform for Pan-Ocular Delivery

SmartCelle for Pan-Ocular Delivery

 The small size (30nm)  and neutral charge of SmartCelle micelles enables increased access of TA-A001 and other TALLC drugs to the cornea, the trabecular network, the anterior chamber and the posterior chamber. Passage through  the aqueous channels of the sclera also allows access to the retinal pigment epithelium (RPE) and inner retinal layer.  TA-A001 is not an efflux pump substrate.

Safety and Tolerability

SmartCelle micelles are well tolerated after repeated instillation or intravenous administration at high concentration. Their low molecular weight and biodegradability allows predominantly renal clearance.



Phone: 514 883 3447



TALLC Corporation Announces Grant of New SmartCelle Patent for
Enhanced Ocular Delivery of TA-A001

Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001

TALLC Launches New Ophthalmology Drug WebSite:

TALLC Inc. is an emerging ophthalmology company developing novel mechanism medicines to treat acute and chronic conditions of the eye. Visit our website to learn more about TA-A001,…

Load More...
TALLC Innovation in Vision

© TALLC Inc. 2020